SCHEMBL16616474

SCHEMBL16616474

COc1ccc(C(=O)/C=C/c2cccnc2Nc2ccccc2)cc1[N+](=O)[O-]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
ALDH1A1 P00352 9/20 0.53
TDP1 Q9NUW8 2/20 0.53
CYP3A4 P08684 1/20 0.53
TSHR P16473 1/20 0.53
LMNA P02545 5/20 0.50
MAPT P10636 5/20 0.50
NPSR1 Q6W5P4 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
GAA P10253 2/20 0.47
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DPP4 P27487 1/20 0.47
PREP P48147 1/20 0.47
DPP9 Q86TI2 1/20 0.47
POLB P06746 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
HTT P42858 2/20 0.47
AR P10275 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16616476 1.00 KMT2A (0.55) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616830 0.93 MAPT (0.49) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16625587 0.93 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616827 0.93 MAPT (0.49) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616377 0.93 MAPT (0.51) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616376 0.93 MAPT (0.51) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616250 0.92 MAPT (0.50) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616395 0.92 LMNA (0.48) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616394 0.92 LMNA (0.48) KMT2AMEN1ALDH1A1TDP1CYP3A4
SCHEMBL16616247 0.92 MAPT (0.50) KMT2AMEN1ALDH1A1TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof HCCS, WEE2, WEE1 KMT2A 2973/4885MEN1 2511/4885ALDH1A1 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.